SCHEMBL274298

SCHEMBL274298

Cc1cccc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2ccno2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 3/20 0.48
MGAM O43451 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48
KMT2A Q03164 6/20 0.46
MEN1 O00255 5/20 0.46
NPC1 O15118 4/20 0.46
HPGD P15428 1/20 0.45
POLB P06746 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
PLEC Q15149 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
OPRK1 P41145 1/20 0.44
LMNA P02545 2/20 0.43
GUSB P08236 1/20 0.43
GFER P55789 1/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266761 1.00 RAB9A (0.54) RAB9ASMN1; SMN2GAAMGAMSI
SCHEMBL266828 0.90 GAA (0.48) RAB9ASMN1; SMN2GAAMGAMSI
SCHEMBL273719 0.90 GAA (0.48) RAB9ASMN1; SMN2GAAMGAMSI
SCHEMBL273872 0.88 GAA (0.47) RAB9ASMN1; SMN2GAAKMT2AMEN1
SCHEMBL267441 0.88 GAA (0.47) RAB9ASMN1; SMN2GAAKMT2AMEN1
SCHEMBL273256 0.85 NPC1 (0.60) RAB9ASMN1; SMN2GAAMGAMSI
SCHEMBL268158 0.85 NPC1 (0.60) RAB9ASMN1; SMN2GAAMGAMSI
SCHEMBL274137 0.84 RAB9A (0.57) RAB9ASMN1; SMN2GAAMGAMSI
SCHEMBL268992 0.84 RAB9A (0.57) RAB9ASMN1; SMN2GAAMGAMSI
SCHEMBL266915 0.84 RAB9A (0.63) RAB9ASMN1; SMN2GAAMGAMSI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885SMN1; SMN2 4253/4885GAA 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.